Merus announces first patient dosed in LiGeR-HN2 trial

Merus announced that the first patient has been dosed in the Company’s phase 3 trial evaluating the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5, compared to investigator’s choice of single agent chemotherapy or cetuximab in previously treated patients with recurrent/metastatic head and neck squamous cell carcinoma, r/m HNSCC, referred to as the LiGeR-HN2 trial. Merus has confirmed through feedback with the U.S. Food and Drug Administration, FDA, that petosemtamab 1500 mg every two weeks is appropriate for further development in HNSCC as monotherapy, and in combination with pembrolizumab. “With petosemtamab’s strong clinical data in HNSCC and alignment with the FDA on dose, we are excited to have treated our first patient in the 2/3L phase 3 trial,” said Fabian Zohren, M.D., Ph.D., Chief Medical Officer of Merus. “We believe petosemtamab has the potential to become the new standard of care across r/m HNSCC.”